Teva and Takeda fill in details on new Japan generics JV

Generic powerhouse Teva Pharmaceutical Industries ($TEVA) and Takeda said last year that they were working a deal to sell generics in Japan, a piece of the market expected to grow significantly as the government pushes off-patent drugs. Now the two have released details about how they will do that. The companies said they will shift to the new company products that include Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes. In a statement, they said those drugs generated sales in 2014 of ¥125 billion ($1.03 billion) in fiscal 2014. Read more from FiercePharmaAsia

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.